Twelve years after founding now globally recognized Moderna, Kenneth Chien is dipping his toes back into the piping hot waters of mRNA startups.

Lytic Solutions has circled in on NightHawk Biosciences’ monkeypox vaccine science, penning a licensing deal with the ultimate goal of developing a vaccine that will address a potential monkeypox pandemic.

Just a few weeks into the full-scale rollout of its Omnipod 5 insulin pump, Insulet has gotten the green light to expand the device’s reach even further.

Accidental falls are the second leading cause of injury-related death across the entire global population, and they take the top spot for people aged 65 and older. Centers for Disease Control and Prevention data show that fall death rates for that age group rose by about 30% between 2009 and 2018.

Novartis’ multiple sclerosis therapy Gilenya was once proposed as a kidney disease treatment because its ability to modulate S1P receptors could theoretically tamp down inflammation. Although that idea didn’t pass the clinical test, the search for better kidney disease drugs targeting the same pathway remains ongoing.

Blood pressure monitoring technology has come a long way in the century since the first inflatable cuff was introduced. Newer models offer digital readings and smartphone connectivity and have even begun to ditch the cuffs in favor of slimmed-down sensors.

The FDA has greenlighted Curis’ phase 1/2 lymphoma trial, lifting a partial clinical hold on the study assessing emavusertib. Yet, a partial hold remains for the biotech’s leukemia trial evaluating the same drug.

In the early stages of pregnancy, as well as during the in vitro fertilization process and after multiple miscarriages, a test may be offered to detect any abnormalities in the fetal chromosomes. Those abnormalities—causing either missing or extra chromosomes—can lead to congenital and genetic disorders or, in some cases, miscarriage.

Apolipoprotein E (Apoe) has not just now hit scientists’ radar. The gene is a major player in the brain and has been associated with Alzheimer’s disease given its ability to switch the role of microglia from a homeostatic role to neurodegenerative.

With competitors laps ahead on the track, CureVac and GSK are loading into the starting block for the COVID-19 booster race. The companies announced Thursday morning that a phase 1 trial for their mRNA booster vaccine targeting the omicron variant is getting underway.